Compare Stocks → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AGTCNASDAQ:FENCNASDAQ:INMBNASDAQ:LOGC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGTCApplied Genetic Technologies$0.39$0.39$0.23▼$2.83$26.62M1.55943,490 shsN/AFENCFennec Pharmaceuticals$9.12-0.4%$10.05$6.30▼$11.92$247.15M0.38114,242 shs55,413 shsINMBINmune Bio$11.49+6.0%$11.40$6.50▼$14.74$209.12M1.9996,050 shs23,078 shsLOGCLogicBio Therapeutics$2.07$2.06$0.26▼$3.77$68.23M4.61652,526 shsN/AElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGTCApplied Genetic Technologies0.00%0.00%0.00%0.00%0.00%FENCFennec Pharmaceuticals+0.99%-4.28%-15.89%-7.47%+12.25%INMBINmune Bio+2.07%+23.18%-8.75%-10.26%+55.30%LOGCLogicBio Therapeutics0.00%0.00%0.00%0.00%0.00%The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside himMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGTCApplied Genetic TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AFENCFennec Pharmaceuticals2.778 of 5 stars3.50.00.00.03.12.51.9INMBINmune Bio1.4794 of 5 stars3.51.00.00.03.11.70.0LOGCLogicBio TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGTCApplied Genetic TechnologiesN/AN/AN/AN/AFENCFennec Pharmaceuticals3.00Buy$17.3390.06% UpsideINMBINmune Bio3.00Buy$16.0039.25% UpsideLOGCLogicBio TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest FENC, LOGC, AGTC, and INMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2024FENCFennec PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$16.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGTCApplied Genetic Technologies$320K83.19N/AN/A$0.26 per share1.51FENCFennec Pharmaceuticals$21.25M11.63N/AN/A($0.43) per share-21.21INMBINmune Bio$160K1,306.99N/AN/A$2.07 per share5.55LOGCLogicBio Therapeutics$5.41M12.61N/AN/A$0.48 per share4.31Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGTCApplied Genetic Technologies-$68.94M-$1.46N/AN/AN/AN/A-192.90%-92.54%N/AFENCFennec Pharmaceuticals-$16.05M-$0.61N/A13.03N/A-75.50%N/A-73.64%5/9/2024 (Estimated)INMBINmune Bio-$30.01M-$1.67N/A∞N/A-19,360.00%-64.11%-45.57%5/1/2024 (Estimated)LOGCLogicBio Therapeutics-$40.03M-$0.81N/AN/AN/A-246.71%-115.29%-53.01%N/ALatest FENC, LOGC, AGTC, and INMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023INMBINmune BioN/A-$0.47-$0.47-$0.47N/A$0.03 million3/21/2024Q4 2023FENCFennec Pharmaceuticals$0.02-$0.10-$0.12-$0.10$9.47 million$9.74 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGTCApplied Genetic TechnologiesN/AN/AN/AN/AN/AFENCFennec PharmaceuticalsN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ALOGCLogicBio TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGTCApplied Genetic Technologies0.391.401.40FENCFennec PharmaceuticalsN/A3.563.27INMBINmune BioN/A2.162.16LOGCLogicBio Therapeutics0.171.992.26OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGTCApplied Genetic Technologies22.05%FENCFennec Pharmaceuticals55.51%INMBINmune Bio12.72%LOGCLogicBio Therapeutics39.11%Insider OwnershipCompanyInsider OwnershipAGTCApplied Genetic Technologies4.10%FENCFennec Pharmaceuticals11.25%INMBINmune Bio36.10%LOGCLogicBio Therapeutics8.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGTCApplied Genetic Technologies8367.63 million64.86 millionOptionableFENCFennec PharmaceuticalsN/A27.10 million24.05 millionOptionableINMBINmune Bio1118.20 million11.63 millionOptionableLOGCLogicBio Therapeutics6232.96 million30.29 millionNot OptionableFENC, LOGC, AGTC, and INMB HeadlinesSourceHeadlineRVVTF Revive Therapeutics Ltd.seekingalpha.com - March 27 at 7:29 AMLogicBio's IPO: What You Need To Knowfinance.yahoo.com - September 24 at 9:29 AMRare Diseases Market is projected to grow at a CAGR of 12.27% by 2033: Visiongain Reports Ltduk.finance.yahoo.com - March 31 at 7:12 PMAlexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeuticsfinance.yahoo.com - November 16 at 5:21 PMLogicBio Therapeutics, Inc.: LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updatesfinanznachrichten.de - November 14 at 2:54 PMLogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updatesfinance.yahoo.com - November 14 at 9:53 AMShort Volatility Alert: LogicBio Therapeutics, Inc.benzinga.com - November 7 at 6:30 PMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SMBC, BTRS, LOGC, RCORkentuckytoday.com - October 23 at 11:01 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOGC, IMRA, SBTXmarketwatch.com - October 17 at 10:54 PMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOGC, FCRD, IMRAbignewsnetwork.com - October 16 at 4:39 PMAlexion, AstraZeneca Rare Disease to Acquire LogicBio Therapeuticsfinsmes.com - October 4 at 8:38 PMINVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of LogicBio Therapeutics, Inc. - LOGCbenzinga.com - October 4 at 10:37 AMLooking Into LogicBio Therapeutics's Recent Short Interestmsn.com - October 3 at 7:50 PMLogicBio Therapeutics Shares Soar on Takeover by AstraZeneca >LOGCmarketwatch.com - October 3 at 2:49 PMAstraZeneca acquires local startup at 660% premiumbizjournals.com - October 3 at 2:49 PMLogicBio's stock skyrockets after buyout bid for a 667% premiumfinance.yahoo.com - October 3 at 2:49 PMAstraZeneca pays 660% premium for gene therapy firm LogicBiomsn.com - October 3 at 9:48 AMLogicBio To Be Bought By Alexion, AstraZeneca Rare Diseasenasdaq.com - October 3 at 9:48 AMAstraZeneca to Buy LogicBio Therapeutics for $68 Million >LOGCmarketwatch.com - October 3 at 9:48 AMWhy LogicBio Therapeutics Stock Is Soaring Todaymsn.com - October 3 at 9:48 AMAlexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicinefinance.yahoo.com - October 3 at 9:48 AMLogicBio® Therapeutics Announces Pre-Clinical Results for mLB-001 Published in Peer-reviewed Journal PLOS ONEfinance.yahoo.com - September 21 at 10:19 AMLogicBio Therapeutics Increuters.com - September 1 at 12:36 PMEarnings Update: LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported And Analysts Are Boosting Their Estimatesfinance.yahoo.com - August 18 at 11:11 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsApplied Genetic TechnologiesNASDAQ:AGTCApplied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.Fennec PharmaceuticalsNASDAQ:FENCFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.INmune BioNASDAQ:INMBINmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03 develop pre-clinical data in cancer that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.LogicBio TherapeuticsNASDAQ:LOGCLogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.